Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Through the use of surrogate markers of efficacy, neoadjuvant studies may facilitate the implementation of new treatments into clinical practice. However, disease-free survival is the current standard outcome endpoint for registration of a novel treatment. The coupling of smaller neoadjuvant 'p...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Snoj, Natasa, Bedard, Philippe L, de Azambuja, Evandro, Cardoso, Fatima, Piccart, Martine
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2687702/
https://ncbi.nlm.nih.gov/pubmed/19216727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2209
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki